Pan‑immune‑inflammatory Values Predict Survival in Patients After Radical Surgery for Non‑metastatic Colorectal Cancer: A Retrospective Study

Overview

Journal Oncol Lett

Specialty Oncology

Date 2025 Mar 6

PMID 40046636

Authors

Kejin Li

Xiangyue Zeng

Ziyi Zhang

Kuan Wang

Yipeng Pan

Zhimin Wu

Yi Chen

Zeliang Zhao

Affiliations

Soon will be listed here.

Abstract

The present study aimed to further investigate the predictive value of pan-immune-inflammatory values (PIVs) in patients with non-metastatic colorectal cancer after radical surgery. Additionally, the study sought to develop a predictive scoring model to predict the survival of patients with colorectal cancer after surgery. A total of 470 non-metastatic patients who attended The Affiliated Cancer Hospital of Xinjiang Medical University (Urumqi, China) for radical colorectal cancer surgery were retrospectively collected based on specific inclusion and exclusion criteria. Patients were categorized into the Low-PIV group and the High-PIV group according to the optimal cut-off value of PIV and a survival analysis was performed. Cox regression was performed for one-way multifactorial analysis. After independent risk factors were screened, a simple score prediction model was constructed and evaluated. The study indicated that PIV was significantly associated with the T stage, Tumor-Node-Metastasis stage, differentiated degree and nerve invasion (all P<0.05). Survival tanalysis showed that patients in the Low-PIV group had a significantly higher 5-year overall survival (OS) rate compared with those in the High-PIV group (88.7 vs. 46.3%; P<0.001). Through multifactorial Cox regression analysis, N stage [hazard ratio (HR), 2.00; 95% confidence interval (CI), 1.04-3.84; P=0.039], differentiated degree (HR, 1.98; 95% CI, 1.16-3.38; P=0.012), neutrophil/lymphocyte ratio (HR, 4.00; 95% CI, 2.19-7.29; P<0.001) and PIV (HR, 4.12; 95% CI, 2.04-8.32; P<0.001) were found to be independent predictors of OS. These variables were included in a column chart to create a scoring system. The concordance index was 0.789 (95% CI, 0.746-0.832). The 1-, 3- and 5-year calibration curves for this column-line diagram demonstrated high confidence. The area under the curve of the predictive model for 1-, 3- and 5-year OS were 0.823, 0.845 and 0.845, respectively. PIV was shown to be a reliable biomarker for the prognosis of patients with non-metastatic colorectal cancer. The current simple predictive scoring model can predict the effective survival of patients following radical surgery for non-metastatic colorectal cancer and could therefore play a substantial role in clinical decision-making.

References

Takahashi T, KUNIYASU Y, Toda M, Sakaguchi N, Itoh M, Iwata M . Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol. 1999; 10(12):1969-80. DOI: 10.1093/intimm/10.12.1969. View

Baba Y, Nakagawa S, Toihata T, Harada K, Iwatsuki M, Hayashi H . Pan-immune-inflammation Value and Prognosis in Patients With Esophageal Cancer. Ann Surg Open. 2023; 3(1):e113. PMC: 10431581. DOI: 10.1097/AS9.0000000000000113. View

Ugel S, Cane S, De Sanctis F, Bronte V . Monocytes in the Tumor Microenvironment. Annu Rev Pathol. 2021; 16:93-122. DOI: 10.1146/annurev-pathmechdis-012418-013058. View

Ligorio F, Fuca G, Zattarin E, Lobefaro R, Zambelli L, Leporati R . The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab. Cancers (Basel). 2021; 13(8). PMC: 8073809. DOI: 10.3390/cancers13081964. View

Yang X, Liu H, Liu D, Tong C, Liang X, Chen R . Prognostic value of pan-immune-inflammation value in colorectal cancer patients: A systematic review and meta-analysis. Front Oncol. 2023; 12:1036890. PMC: 9813847. DOI: 10.3389/fonc.2022.1036890. View

Wesselink E, Balvers M, Kok D, Winkels R, van Zutphen M, Schrauwen R . Levels of Inflammation Markers Are Associated with the Risk of Recurrence and All-Cause Mortality in Patients with Colorectal Cancer. Cancer Epidemiol Biomarkers Prev. 2021; 30(6):1089-1099. DOI: 10.1158/1055-9965.EPI-20-1752. View

Schmitt M, Greten F . The inflammatory pathogenesis of colorectal cancer. Nat Rev Immunol. 2021; 21(10):653-667. DOI: 10.1038/s41577-021-00534-x. View

Siegel R, Miller K, Wagle N, Jemal A . Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. DOI: 10.3322/caac.21763. View

Gu L, Li H, Chen L, Ma X, Li X, Gao Y . Prognostic role of lymphocyte to monocyte ratio for patients with cancer: evidence from a systematic review and meta-analysis. Oncotarget. 2016; 7(22):31926-42. PMC: 5077986. DOI: 10.18632/oncotarget.7876. View

10.

Grivennikov S, Greten F, Karin M . Immunity, inflammation, and cancer. Cell. 2010; 140(6):883-99. PMC: 2866629. DOI: 10.1016/j.cell.2010.01.025. View

11.

Chen Y, Zhang Y, Wang Z, Wang Y, Luo Y, Sun N . CHST15 gene germline mutation is associated with the development of familial myeloproliferative neoplasms and higher transformation risk. Cell Death Dis. 2022; 13(7):586. PMC: 9263130. DOI: 10.1038/s41419-022-05035-w. View

12.

Engblom C, Pfirschke C, Pittet M . The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016; 16(7):447-62. DOI: 10.1038/nrc.2016.54. View

13.

Shayimu P, Awula M, Wang C, Jiapaer R, Pan Y, Wu Z . Serum nutritional predictive biomarkers and risk assessment for anastomotic leakage after laparoscopic surgery in rectal cancer patients. World J Gastrointest Surg. 2024; 16(10):3142-3154. PMC: 11577407. DOI: 10.4240/wjgs.v16.i10.3142. View

14.

Apte R, Dotan S, Elkabets M, White M, Reich E, Carmi Y . The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev. 2006; 25(3):387-408. DOI: 10.1007/s10555-006-9004-4. View

15.

Zhang F, Wu Z, Sun S, Fu Y, Chen Y, Liu J . POEMS syndrome in the 21st century: A bibliometric analysis. Heliyon. 2023; 9(10):e20612. PMC: 10570589. DOI: 10.1016/j.heliyon.2023.e20612. View

16.

Seo Y, Kim K, Jeong W, Baek S, Bae S . Effect of preoperative pan-immune-inflammation value on clinical and oncologic outcomes after colorectal cancer surgery: a retrospective study. Ann Surg Treat Res. 2024; 106(3):169-177. PMC: 10902619. DOI: 10.4174/astr.2024.106.3.169. View

17.

Quail D, Amulic B, Aziz M, Barnes B, Eruslanov E, Fridlender Z . Neutrophil phenotypes and functions in cancer: A consensus statement. J Exp Med. 2022; 219(6). PMC: 9086501. DOI: 10.1084/jem.20220011. View

18.

Yamamoto T, Kawada K, Obama K . Inflammation-Related Biomarkers for the Prediction of Prognosis in Colorectal Cancer Patients. Int J Mol Sci. 2021; 22(15). PMC: 8348168. DOI: 10.3390/ijms22158002. View

19.

Algra A, Rothwell P . Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012; 13(5):518-27. DOI: 10.1016/S1470-2045(12)70112-2. View

20.

Li M, Liu X, Zhang X, Zhang J, Wang W, Zhu Y . Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis. Int J Cancer. 2013; 134(10):2403-13. DOI: 10.1002/ijc.28536. View